People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ARYx Therapeutics, Inc. | — | Pharmaceuticals | Seed | $2.4M | $76.6M | 2009 |
John G. Varian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John G. Varian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| PAUL SEKHRI | 1 | 7 |
| Paul Goddard | 1 | 4 |
| Lars G. Ekman | 1 | 3 |
| Nick Simon | 1 | 3 |
| Keith Leonard | 1 | 3 |
| Lars Ekman | 1 | 2 |
| Peter G Milner | 1 | 2 |
| Pascal Druzgala | 1 | 2 |
| Paul G. Sekhri | 1 | 2 |
| Daniel G. Canafax | 1 | 1 |
| David G. Nagler | 1 | 1 |
| Keith G. Leonard | 1 | 1 |
| David Beier | 1 | 1 |
| John Varian | 1 | 1 |
| David Nagler | 1 | 1 |
| Hermn Rosenman | 1 | 1 |
| Nick G. Simon | 1 | 1 |
| Herm G. Rosenman | 1 | 1 |
| David G. Beier | 1 | 1 |
| Pascal G. Druzgala | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.